All Blogs
Feb 19, 2026
Medtronic Wins FDA Green Light for Stealth AXiS; Retia Medical Secures FDA 510(k) Clearance for Argos Infinity; Danaher Announces Plan to Acquire Masimo Corporation; Dynarex Introduces New Advanced Negative Pressure Therapy Device; Valcare Medical Reports First U.S. Transseptal AMEND™ Implant in Early Feasibility Study; Envoy Medical Reports Enrollment Nearly Complete for Acclaim Cochlear Implant Pivotal Trial
Medtronic Received FDA Clearance for Stealth AXiS™ Surgical System, First Integrated Planning, Navigation and Robotics Platform for Spine Surgery On February 13, 2026, Medtronic, a global leader in healthcare technology, announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical sy...
Read More...
Feb 18, 2026
Diabetes Care Devices: Transforming Management Through Innovation and Precision
Diabetes care devices are becoming increasingly vital as the global burden of diabetes continues to rise. Today, more than 530 million adults worldwide live with diabetes, a number projected to increase in the future. The condition requires continuous monitoring and timely intervention to prevent serious complicati...
Read More...
Feb 17, 2026
Roche’s GAZYVA/GAZYVARO Achieves Key Phase III Success in Primary Membranous Nephropathy; Novartis’ VANRAFIA Slows Kidney Function Decline in Phase III IgA Nephropathy Trial; PTC Therapeutics Shares Latest Regulatory Developments for Translarna; BridgeBio’s Oral Infigratinib Achieves Key Body Proportionality Improvements in Phase 3 Achondroplasia Trial; Upstream Bio’s Verekitug Achieves Key Endpoints in Phase 2 Trial for Severe Asthma Treatment
Roche Reports Positive Phase III Data for GAZYVA/GAZYVARO in Primary Membranous Nephropathy Roche has reported highly encouraging results from the Phase III MAJESTY study, which evaluated the efficacy and safety of GAZYVA/GAZYVARO (obinutuzumab) in adults suffering from primary membranous nephropathy (PMN). PMN ...
Read More...
Feb 16, 2026
Alternative Therapeutic Strategies Beyond HSCT: Reimagining Curative Options in Hematologic Disease
Summary HSCT is a potentially curative treatment for hematologic malignancies (acute leukemias, lymphomas, multiple myeloma) and bone marrow failure syndromes. In 2025, approximately 26,000 HSCT cases were reported in the 7MM, with Multiple Myeloma/Plasma Cell Dyscrasias having the largest patient pool in th...
Read More...
Feb 13, 2026
The Next Frontier in Bardet–Biedl Syndrome Treatment: Gene Therapy and Beyond
Summary Bardet–Biedl syndrome (BBS) is a rare, genetically heterogeneous disorder that affects more than 5,000 individuals in the United States. A major therapeutic milestone was the approval of IMCIVREE (setmelanotide), the first targeted MC4R agonist therapy addressing BBS-related obesity. Gene th...
Read More...
Feb 12, 2026
Hologic Gains FDA Clearance for Aptima® HPV Assay as Primary Screening Tool; ZOLL Zenix Monitor/Defibrillator Achieves MDR Approval; Labcorp Unveils FDA-Cleared Blood Test for Alzheimer’s Screening; P&F SecureD EU MDR CE Mark Approval for the TricValve® System; Valcare Medical Performs First U.S. Transseptal AMEND™ Implant as Part of Early Feasibility Study; Hyperfine Unveils New Clinical Results Showing Improved Stroke Detection with the Swoop® System
Hologic Received FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio On February 04, 2026, Hologic, Inc. announced that its Aptima® HPV Assay had received FDA approval for clinician-collected HPV primary screening. The test, which was the only FDA-approved mRNA-...
Read More...
Feb 11, 2026
The Future of Pain Management Devices: AI and Digital Integration
The convergence of artificial intelligence and connected health technologies is fundamentally transforming chronic pain management, shifting from reactive treatment protocols to proactive, personalized care systems. This integration represents not merely an incremental improvement but a paradigm shift in how patien...
Read More...
Feb 10, 2026
Sanofi Advances wAIHA Program as Rilzabrutinib Receives Breakthrough and Orphan Status; Lilly Moves to Acquire Orna Therapeutics, Expanding Cell Therapy Portfolio; Roche Announces Key PPMS Trial Success for Fenebrutinib; Priovant’s Brepocitinib Demonstrates Strong Potential in Phase 2 Cutaneous Sarcoidosis Study; AstraZeneca’s DATROWAY Grants US Priority Review for 1L mTNBC Indication in Patients not Eligible for Immunotherapy
Sanofi’s Rilzabrutinib Granted Breakthrough and Orphan Designations for wAIHA Rilzabrutinib (WAYRILZ) by Sanofi (EPA: SAN) recently achieved two major regulatory milestones: FDA Breakthrough Therapy Designation in the U.S. and Orphan Drug Designation by the Japanese Ministry of Health, Labour and Welfare for the...
Read More...
Feb 09, 2026
Drug-Resistant Epilepsy: Evolving Treatment Strategies for a High‑Unmet‑Need Population
Summary Drug-resistant epilepsy affects 20-40% of epilepsy patients in the US, rising to 30-40% in adults versus 7-20% in children, with similar rates (over 25%) in Europe; about one-quarter of newly diagnosed cases progress to DRE. Vagus Nerve Stimulation (VNS Therapy by LivaNova) is FDA-approved for drug-r...
Read More...
Feb 06, 2026
Menin Inhibitors: A Revolutionary Treatment Paradigm for Acute Leukemia
Summary Menin inhibitors are an emerging class of targeted therapies that transform treatment for genetically defined acute leukemias, particularly KMT2A‑rearranged and NPM1‑mutated AML. REVUFORJ (revumenib, Syndax) is the first FDA‑approved selective menin inhibitor for relapsed/refractory acute leukemia wi...
Read More...